Mirati Therapeutics Inc.’s update on the phase I/II Krystal trial of the KRAS-G12C-targeting adagrasib (MRTX-849) was arguably the most eagerly awaited news, and certainly the most eagerly awaited KRAS-targeting news, to come out of the 2020 EORTC-NCI-AACR (ENA) Molecular Targets meeting. KRAS is one of the most frequently mutated oncogenes across a wide swath of solid tumors, and has been one of the toughest nuts to crack as far as druggability is concerned.

BioWorld looks at translational medicine, including: Prenatal treatment normalizes brain development in Down syndrome model.

BioWorld looks at translational medicine, including: Engineered opsin restores vision.

A multi-institutional team of researchers has implicated lipid droplets, which are key energy storage units of individual cells, in innate immune defense.

Investigators at the ECOG-ACRIN Cancer Research Group and the National Cancer Institute reported a roughly 40% match rate of patients to molecularly targeted therapies in its NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial, ultimately leading to molecularly targeted treatments for almost 20% of trial participants.

BioWorld looks at translational medicine, including: PDAC subtypes point to targeting strategies; Lactose tolerance may be Red Herring.

“It’s coming. We know it’s coming.” That was Nevan Krogan’s blunt reminder that SARS-CoV-2 is not the first virus to wreak temporary havoc on humanity, nor will it be the last.

BioWorld looks at translational medicine, including: SWI/SNF mutations can lead to gain of function.

Two teams of researchers have developed miniature models of the human heart that beat and function like the full-size organ.

BioWorld looks at translational medicine, including: Neutrophils are literal obstacle to stroke recovery.